The COVID-19 pandemic yielded indirect increases in disease burden for specific causes, including mental health disorders.

The annual growth in national health spending is expected to be faster than average gross domestic product (GDP) growth during 2024 to 2033.

Associations between neighborhood characteristics (e.g. air pollution and neighborhood socioeconomic status) and mental health outcomes varied by age.

Using cannabis for sleep in the past month was associated with worse mental health, more problems from cannabis use, and lower cognitive function.

Patients undergoing retinal detachment (RD) repair with concomitant cannabis use have a lower risk for subsequent proliferative vitreoretinopathy (PVR) and requiring subsequent complex RD repair.

Between 2015 and 2021, dementia incidence decreased and prevalence increased in US Medicare beneficiaries with greater burden in marginalized groups.

Greater neighborhood disadvantage is associated with increased inflammatory and Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers in older adults.

The US Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity disorder (ADHD) medications.

A large percentage of patients with SSc screened positive for ARFID, reporting significant GI symptom burden and reduced HRQOL.

For patients with mild cognitive impairment (MCI) associated with Alzheimer disease (AD), those in the highest tertile of the triglyceride-glucose (TyG) index experience faster cognitive decline.

For individuals with specific autoimmune conditions, there appears to be an increased risk for affective disorders.

Intermittent-fasting strategies yield small reductions in body weight compared with an ad libitum diet, according to a study.